Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report
Oncotarget · 2025
DOI: 10.18632/oncotarget.28682 ↗Kurz gefasst
Fallbericht in der Zeitschrift Oncotarget, 2025. Verfasst von Jenny L Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: Vanderbilt University School of Medicine, Nashville, TN 37232, USA. Hauptthemen laut MEDLINE: Antigens, Differentiation, B-Lymphocyte, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Gene Rearrangement. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
- Vanderbilt-Ingram Cancer Center, Nashville, TN 37232, USA.
Zitieren
APA
Wu, J. L., & Iams, W. T. (2025). Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report. Oncotarget. https://doi.org/10.18632/oncotarget.28682
Vancouver
Wu JL, Iams WT. Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report. Oncotarget. 2025. doi:10.18632/oncotarget.28682
BibTeX
@article{Wu2025,
author = {Wu, Jenny L and Iams, Wade T},
title = {Acquired RUFY1-RET rearrangement as a mechanism of resistance to lorlatinib in a patient with CD74-ROS1 rearranged non-small cell lung cancer: A case report},
journal = {Oncotarget},
year = {2025},
doi = {10.18632/oncotarget.28682}
}
EUVIMED